Traynor Capital Management Inc. Sells 2,045 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Traynor Capital Management Inc. reduced its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 8.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,959 shares of the financial services provider’s stock after selling 2,045 shares during the period. Traynor Capital Management Inc.’s holdings in iShares Biotechnology ETF were worth $3,035,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in IBB. Darwin Wealth Management LLC bought a new position in shares of iShares Biotechnology ETF during the third quarter valued at approximately $29,000. Highline Wealth Partners LLC bought a new position in iShares Biotechnology ETF in the third quarter worth about $30,000. Ashton Thomas Securities LLC acquired a new position in shares of iShares Biotechnology ETF during the third quarter worth $36,000. Modus Advisors LLC acquired a new stake in shares of iShares Biotechnology ETF in the 4th quarter worth $41,000. Finally, Voisard Asset Management Group Inc. purchased a new position in iShares Biotechnology ETF during the 3rd quarter worth $59,000. 62.45% of the stock is currently owned by institutional investors.

iShares Biotechnology ETF Trading Up 0.1 %

iShares Biotechnology ETF stock opened at $136.29 on Thursday. iShares Biotechnology ETF has a one year low of $123.60 and a one year high of $150.57. The stock has a 50-day moving average of $136.00 and a two-hundred day moving average of $141.81.

iShares Biotechnology ETF Cuts Dividend

The business also recently announced a dividend, which was paid on Friday, December 20th. Investors of record on Tuesday, December 17th were paid a $0.0624 dividend. The ex-dividend date of this dividend was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.